еНаука - преглед
Преглед према Аутор Malik, Rajesh K
Приказ резултата 1 до 3 од 3
| Година | Наслов | Аутор(и) | Тип резултата | Мп-кат. |
|---|---|---|---|---|
| 2021 | Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer | Domine, Gomez Manuel; Csoszi, Tibor; Jaal, Jana; Kudaba, Iveta; Nikolov, Krassimir; Radosavljevic, Davorin Z; Xiao, Jie; Horton, Janet K; Malik, Rajesh K; Subramanian, Janakiraman | Научни чланак | 21aM21a - Водећи међународни часопис категорије M21a |
| 2021 | Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). | Goel, Shom; O'Shaughnessy, Joyce; Tan, Antoinette R; Milev-Krastev, Boris; Rugo, Hope S; Aftimos, Philippe Georges; Yardley, Denise A; Andric, Zoran G   ; Wolfgang, Curt Douglas; Sorrentino, Jessica;
Tao, Wenli; Beelen, Andrew Paul; Malik, Rajesh K; Jain, Sarika;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2022 | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 | Goel, Shom; Tan, Antoinette R; Rugo, Hope S; Aftimos, Philippe; Andric, Zoran G ; Beelen, Andrew Paul; Zhang, Jingshan; Yi, John S; Malik, Rajesh K; O'Shaughnessy, Joyce | Article | 22M22 |